CUI1 stringlengths 8 8 | RELA stringlengths 3 54 | CUI2 stringlengths 8 8 | Name1 stringlengths 1 2.86k ⌀ | Name2 stringlengths 1 2.86k ⌀ | Def1 stringlengths 1 8.95k ⌀ | Def2 stringlengths 1 8.95k ⌀ |
|---|---|---|---|---|---|---|
C0000618 | has_ingredient | C0707967 | mercaptopurine | mercaptopurine 50 MG Oral Tablet [Purinethol] | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | has_ingredient | C3817722 | mercaptopurine | mercaptopurine 20 MG/ML Oral Suspension [Purixan] | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | has_active_ingredient | C0689485 | mercaptopurine | mercaptopurine 50 MG Oral Tablet | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | has_active_ingredient | C3817722 | mercaptopurine | mercaptopurine 20 MG/ML Oral Suspension [Purixan] | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | inverse_isa | C1957678 | mercaptopurine | 2-mercaptopurine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | parent_of | C2267095 | mercaptopurine | M [Preparations] | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | tradename_of | C0722911 | mercaptopurine | Purinethol | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | form_of | C1881785 | mercaptopurine | mercaptopurine anhydrous | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | The anhydrous form of mercaptopurine, a thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities. Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioin... |
C0000618 | tradename_of | C3819063 | mercaptopurine | Purixan | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | therapeutic_class_of | C0003392 | mercaptopurine | Antineoplastic Agents | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Substances that inhibit or prevent the proliferation of NEOPLASMS. |
C0000618 | has_contraindicated_drug | C0013182 | mercaptopurine | Drug Allergy | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Immunologically mediated adverse reactions to medicinal substances used legally or illegally. |
C0000618 | may_be_treated_by | C0023434 | mercaptopurine | Chronic Lymphocytic Leukemia | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These t... |
C0000618 | has_contraindicated_drug | C0023895 | mercaptopurine | Liver diseases | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Pathological processes of the LIVER. |
C0000618 | may_be_treated_by | C0024305 | mercaptopurine | Lymphoma, Non-Hodgkin | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease... |
C0000618 | has_contraindicated_drug | C0027947 | mercaptopurine | Neutropenia | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | A decrease in the number of NEUTROPHILS found in the blood. |
C0000618 | has_contraindicated_drug | C0032961 | mercaptopurine | Pregnancy | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. |
C0000618 | has_contraindicated_drug | C0040034 | mercaptopurine | Thrombocytopenia | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | A subnormal level of BLOOD PLATELETS. |
C0000618 | has_ingredient | C0987634 | mercaptopurine | mercaptopurine 50 MG | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | has_ingredient | C1128385 | mercaptopurine | mercaptopurine 10 MG | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | has_ingredient | C1246842 | mercaptopurine | mercaptopurine Oral Tablet | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | The anhydrous form of mercaptopurine, a thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities. Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioin... |
C0000618 | physiologic_effect_of | C1371553 | mercaptopurine | Decreased DNA Integrity | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | physiologic_effect_of | C1371859 | mercaptopurine | Decreased RNA Integrity | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | physiologic_effect_of | C1372180 | mercaptopurine | Increased Cellular Death | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | metabolic_site_of | C1373177 | mercaptopurine | Intestinal Metabolism | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | metabolic_site_of | C1373178 | mercaptopurine | Hepatic Metabolism [PK] | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | may_be_treated_by | C1961102 | mercaptopurine | Precursor Cell Lymphoblastic Leukemia Lymphoma | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias. |
C0000618 | mechanism_of_action_of | C2266855 | mercaptopurine | Nucleoside Synthesis Inhibitors | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mechanism_of_action_of | C2757009 | mercaptopurine | Nucleic Acid Synthesis Inhibitors [MoA] | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | has_ingredient | C3219954 | mercaptopurine | mercaptopurine Oral Product | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | has_ingredient | C3219955 | mercaptopurine | mercaptopurine Pill | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | has_ingredient | C3820132 | mercaptopurine | mercaptopurine 20 MG/ML | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | has_ingredient | C3820263 | mercaptopurine | mercaptopurine Oral Suspension | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | An oral suspension containing the thiopurine-derivative antimetabolite 6-mercaptopurine, with potential antineoplastic activity. Upon oral administration, mercaptopurine is metabolized by hypoxanthine-guanine phosphoribosyltransferase (HGPRTase) to its active metabolite 6-thioinosine monophosphate (TIMP); TIMP inhibits... |
C0000618 | has_ingredient | C3820330 | mercaptopurine | mercaptopurine Oral Liquid Product | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | has_member | C3653380 | mercaptopurine | Purine analogs, antimetabolites antineoplastic | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | measures | C0550716 | mercaptopurine | Mercaptopurine:MCnc:Pt:Ser/Plas:Qn | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | measures | C0800376 | mercaptopurine | Mercaptopurine:PrThr:Pt:Ser/Plas:Ord | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | measures | C1715013 | mercaptopurine | Mercaptopurine:PrThr:Pt:Bld:Ord | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | has_active_metabolites | C0004482 | mercaptopurine | azathioprine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed) |
C0000618 | contraindicated_class_of | C0249529 | mercaptopurine | febuxostat | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | A thiazole derivative and inhibitor of XANTHINE OXIDASE that is used for the treatment of HYPERURICEMIA in patients with chronic GOUT. |
C0000618 | inverse_isa | C0003376 | mercaptopurine | Antimetabolites | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Drugs that are chemically similar to naturally occurring metabolites, but differ enough to interfere with normal metabolic pathways. (From AMA Drug Evaluations Annual, 1994, p2033) |
C0000618 | inverse_isa | C0003377 | mercaptopurine | Antimetabolites, Antineoplastic | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Antimetabolites that are useful in cancer chemotherapy. |
C0000618 | inverse_isa | C0021081 | mercaptopurine | Immunosuppressive Agents | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to preve... |
C0000618 | inverse_isa | C0376568 | mercaptopurine | Nucleic Acid Synthesis Inhibitors | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Compounds that inhibit cell production of DNA or RNA. |
C0000618 | mapped_to | C0049563 | mercaptopurine | 6-ethylthiopurine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0049637 | mercaptopurine | 6-mercapto-9-(tetrahydro-2-furyl)purine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0049668 | mercaptopurine | 6-methylthiopurine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0052852 | mercaptopurine | B-DOMP protocol | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0053541 | mercaptopurine | BH-AC-AMP protocol | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0053542 | mercaptopurine | BH-AC-DMP protocol | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0054253 | mercaptopurine | buthiopurine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0054258 | mercaptopurine | Butocin | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | A S-substituted analog of mercaptopurine and purine antagonist with cytostatic activity. Butocin inhibits purine nucleotide synthesis and DNA replication. |
C0000618 | mapped_to | C0054923 | mercaptopurine | CCG-141 protocol | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0055960 | mercaptopurine | Cloturin | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0057181 | mercaptopurine | cytarabine/daunorubicin/mercaptopurine/prednisolone | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | A regimen consisting of cytarabine, daunorubicin, mercaptopurine, and prednisolone that may be used in the treatment of acute myeloid leukemia (AML). |
C0000618 | mapped_to | C0066786 | mercaptopurine | MOPA-6 protocol | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0069959 | mercaptopurine | palladium-6-mercaptopurine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0071715 | mercaptopurine | Mercaptopurine/Methotrexate/Prednisone/Vincristine Regimen | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | A regimen consisting of mercaptopurine, methotrexate, prednisone and vincristine that may be used in the treatment of acute lymphoblastic leukemia (ALL). |
C0000618 | mapped_to | C0073821 | mercaptopurine | S-(6-purinyl)cysteine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0078153 | mercaptopurine | VEMP protocol 1 | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0143542 | mercaptopurine | St Jude's regimen | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0164292 | mercaptopurine | ACMP protocol | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0173325 | mercaptopurine | AIEOP acute lymphoblastic leukemia protocol | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0211730 | mercaptopurine | carsatrin | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0212440 | mercaptopurine | AIEOP protocol 8202 | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0215655 | mercaptopurine | BHAC-DMPV protocol | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0296116 | mercaptopurine | TOTAL-XII protocol | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0297870 | mercaptopurine | 6-mercaptopurine 7-N-oxide | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0386330 | mercaptopurine | BMF phase II protocol | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0387453 | mercaptopurine | 6-methylmercapto-8-hydroxypurine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0388645 | mercaptopurine | HR-1 protocol | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0390407 | mercaptopurine | BFM-86 protocol | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0531089 | mercaptopurine | M-DOMP protocol | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0536073 | mercaptopurine | POG 8602 protocol | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0601718 | mercaptopurine | 2-piperidino-8-mercaptoadenine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0604783 | mercaptopurine | xylosyl-6-mercaptopurine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0607949 | mercaptopurine | 6-(2,4-dinitrophenyl)mercaptopurine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0618146 | mercaptopurine | bismuth-6-mercaptopurine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0624263 | mercaptopurine | A-VBM-FH6 protocol | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0625550 | mercaptopurine | DOAPP protocol | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0626019 | mercaptopurine | 9-ethyl-6-mercaptopurine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | A synthetic alkyl derivative prodrug of the antineoplastic agent 6-mercaptopurine (6-MP). In vivo, 9-ethyl 6-mercaptopurine appears to be converted to 6-MP, which substitutes for the normal nucleoside and fraudulently incorporates into DNA and inhibits de novo purine synthesis, thereby inducing cell death. (NCI04) |
C0000618 | mapped_to | C0626021 | mercaptopurine | 9-(n-butyl)-6-mercaptopurine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0628889 | mercaptopurine | BFHM protocol | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0632898 | mercaptopurine | protocol 8001 | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0640909 | mercaptopurine | 6-trimethylsilylthio-9-trimethylsilylpurine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0641006 | mercaptopurine | 6-(phenyldithio)purine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0641009 | mercaptopurine | 6-(decyldithio)-1H-purine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0644507 | mercaptopurine | arabinosyl-6-mercaptopurine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0653951 | mercaptopurine | GAP-POMP regimen | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0655632 | mercaptopurine | 7+3 protocol | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0655668 | mercaptopurine | non-Hodgkin's lymphoma protocol 8503 | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0657697 | mercaptopurine | T-8801 protocol | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0661122 | mercaptopurine | POG 8493 protocol | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0662192 | mercaptopurine | ACOP protocol 2 | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0663945 | mercaptopurine | AIEOP 8703 protocol | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0666656 | mercaptopurine | (9H-purin-6-yl)thiomethyl glutamate | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0908960 | mercaptopurine | methyl-6-mercatopurine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C0961033 | mercaptopurine | tris(6-mercaptopurine)iron(II) | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C1101492 | mercaptopurine | BHAC-AMP protocol | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C1174518 | mercaptopurine | ALL-80 protocol | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | mapped_to | C1174519 | mercaptopurine | ALL-82 protocol | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.